Moderna (MRNA) Current Taxes (2021 - 2024)

Moderna (MRNA) has 4 years of Current Taxes data on file, last reported at $4.0 million in Q3 2024.

• On a quarterly basis, Current Taxes fell 92.86% year-over-year to $4.0 million in Q3 2024; TTM through Sep 2024 was $4.0 million, a 92.86% decrease from a year earlier, with the FY2023 full-year figure at $63.0 million, up 31.25% from the prior year.
• Current Taxes for Q3 2024 stood at $4.0 million, down from $7.0 million in the prior quarter.
• Over the last five years, Current Taxes for MRNA reached as high as $1.6 billion in Q1 2022 and fell as low as $4.0 million in Q3 2024.
• Historically, Current Taxes has averaged $291.6 million across 4 years, with a median of $63.0 million in 2023.
• On a YoY basis, Current Taxes climbed as much as 31.25% in 2023 and fell as far as 95.85% in 2023.
• Year by year, Current Taxes stood at $876.0 million in 2021, then slumped by 94.52% to $48.0 million in 2022, then soared by 31.25% to $63.0 million in 2023, then slumped by 93.65% to $4.0 million in 2024.
• Per Business Quant data, the three most recent Current Taxes figures were $4.0 million in Q3 2024, $7.0 million in Q2 2024, and $52.0 million in Q1 2024.